Amgen, Inc. (AMGN)
437.23
-6.89
(-1.55%)
USD |
NASDAQ |
Sep 04, 16:00
415.00
-22.23
(-5.08%)
After-Hours: 20:00
Amgen Research and Development Expense (Quarterly) : 1.868B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.868B |
| March 31, 2026 | 1.719B |
| December 31, 2025 | 2.151B |
| September 30, 2025 | 1.90B |
| June 30, 2025 | 1.744B |
| March 31, 2025 | 1.486B |
| December 31, 2024 | 1.698B |
| September 30, 2024 | 1.45B |
| June 30, 2024 | 1.447B |
| March 31, 2024 | 1.343B |
| December 31, 2023 | 1.522B |
| September 30, 2023 | 1.079B |
| June 30, 2023 | 1.113B |
| March 31, 2023 | 1.058B |
| December 31, 2022 | 1.324B |
| September 30, 2022 | 1.112B |
| June 30, 2022 | 1.039B |
| March 31, 2022 | 959.00M |
| December 31, 2021 | 1.348B |
| September 30, 2021 | 1.422B |
| June 30, 2021 | 1.082B |
| March 31, 2021 | 967.00M |
| December 31, 2020 | 1.229B |
| September 30, 2020 | 1.062B |
| June 30, 2020 | 964.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 952.00M |
| December 31, 2019 | 1.312B |
| September 30, 2019 | 1.001B |
| June 30, 2019 | 924.00M |
| March 31, 2019 | 879.00M |
| December 31, 2018 | 1.182B |
| September 30, 2018 | 926.00M |
| June 30, 2018 | 869.00M |
| March 31, 2018 | 760.00M |
| December 31, 2017 | 1.043B |
| September 30, 2017 | 877.00M |
| June 30, 2017 | 873.00M |
| March 31, 2017 | 769.00M |
| December 31, 2016 | 1.078B |
| September 30, 2016 | 990.00M |
| June 30, 2016 | 900.00M |
| March 31, 2016 | 872.00M |
| December 31, 2015 | 1.077B |
| September 30, 2015 | 1.106B |
| June 30, 2015 | 946.00M |
| March 31, 2015 | 877.00M |
| December 31, 2014 | 1.20B |
| September 30, 2014 | 1.003B |
| June 30, 2014 | 1.018B |
| March 31, 2014 | 1.027B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.69B |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| AbbVie, Inc. | 2.344B |
| Biogen, Inc. | 461.70M |
| Vertex Pharmaceuticals, Inc. | 993.80M |